The Upstream Bio, Inc. (NASDAQ: UPB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances verekitug, a monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor, through clinical development. As a clinical-stage biotechnology company, Upstream Bio uses SEC reports to communicate trial progress, financial results, and other material information relevant to shareholders.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results and business highlights, as well as the furnishing of press releases and presentations. For example, an 8-K dated August 6, 2025, furnished a press release summarizing second quarter financial results and updates on Phase 2 trials in CRSwNP, severe asthma, and COPD. Another 8-K dated November 5, 2025, furnished third quarter results and program progress, while an 8-K dated September 2, 2025, furnished the press release and presentation describing positive top-line data from the VIBRANT Phase 2 CRSwNP trial.
Through these filings, investors can see how Upstream Bio reports collaboration revenue, research and development expenses related to verekitug, general and administrative expenses, and net loss figures, as well as balance sheet items such as cash, cash equivalents, and short-term investments. The filings also describe the design and endpoints of key clinical trials when they are the subject of a furnished press release.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight the main points of each filing, helping readers quickly understand what changed in a given quarter or event filing. Users can review 8-Ks tied to clinical data releases, financial updates, and other corporate communications, and use this information alongside news and price data when evaluating UPB.
For Upstream Bio, Inc., Decheng Capital Global Life Sciences Fund IV, L.P. reported beneficial ownership of 2,724,868 common shares as of September 30, 2026, or 4.98% of the class. The fund held the shares directly; its general partner, Decheng Capital Management IV (Cayman), LLC, and manager Xiangmin Cui reported shared voting and investment authority over the same shares. The percentage calculation used 54,771,041 shares outstanding as of August 4, 2026.
Upstream Bio, Inc. (UPB) reported that its CFO and COO, Michael Gray, sold 853 shares of common stock on September 16, 2026 at $5.49 per share. According to the company’s sell-to-cover policy, this automatic sale was made solely to satisfy tax withholding obligations arising from the vesting of restricted stock units, not at the officer’s discretion. Following the transaction, Gray directly held 27,942 shares of Upstream Bio common stock.
Upstream Bio, Inc. (UPB) reported that its General Counsel, Allison Ambrose, sold 485 shares of common stock on September 16, 2026 at $5.49 per share. The company states this was an automatic sell-to-cover transaction to satisfy tax withholding on vesting restricted stock units, not at the executive’s discretion, leaving 15,563 shares held directly.
Upstream Bio, Inc. (UPB) reported that its Chief Medical Officer, Aaron Deykin, sold 895 shares of common stock on September 16, 2026 at $5.49 per share. According to the company’s disclosure, this was an automatic “sell-to-cover” transaction to satisfy tax withholding obligations from vesting restricted stock units and was not at his discretion. After the sale, he directly holds 32,302 shares of Upstream Bio common stock.
Upstream Bio, Inc. (UPB) reported that Chief Executive Officer and director Everett Rand Sutherland sold 2,095 shares of common stock on September 16, 2026 at $5.49 per share. According to the company’s policy, the sale was an automatic “sell-to-cover” transaction to satisfy tax withholding obligations from vesting restricted stock units, and was not at Sutherland’s discretion. Following this sale, he directly holds 68,717 shares of Upstream Bio common stock.
Upstream Bio, Inc. (UPB) reported that Chief Business Officer Adam Houghton sold 700 shares of common stock on September 16, 2026 at $5.49 per share in an open-market or private transaction. After this sale, he held 22,901 shares directly.
According to the company’s disclosed sell-to-cover policy, these sales were made automatically to satisfy tax withholding obligations arising from the vesting of restricted stock units, and were not at Houghton’s discretion. No Rule 10b5-1 trading plan is reported for this transaction.
Upstream Bio, Inc. (UPB) outlined pivotal Phase 3 development plans for its lead drug candidate verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company will run one placebo-controlled Phase 3 trial in each indication using a single high-dose 400 mg subcutaneous regimen administered every 12 weeks, enrolling approximately 1,500 patients in total.
Primary endpoints include annualized asthma exacerbation rates over 48 weeks for asthma and co-primary nasal polyp and congestion scores at 48 weeks for CRSwNP. Upstream Bio plans to initiate both Phase 3 trials in the first quarter of 2027 and, with supportive results, expects to submit BLAs to the FDA for both indications, targeting potential U.S. launch of verekitug as early as 2030. Verekitug has already been studied in more than 500 participants with positive Phase 2 results in severe asthma and CRSwNP and is also being evaluated in an ongoing Phase 2 COPD trial.
Norges Bank, the central bank of Norway and an investment adviser, reports its beneficial ownership of common stock of Upstream Bio, Inc. on an amended Schedule 13G. Norges Bank reports beneficial ownership of 4,206,586 shares of common stock, representing 7.7299% of the class.
Of this position, Norges Bank has 3,768,619 shares with sole power to vote and 3,768,619 shares with sole power to dispose. It reports 437,967 shares with shared power to dispose and no shared voting power. Certain shares are reported as invested on behalf of the Government of Norway, and Norges Bank certifies that its foreign regulatory scheme is substantially comparable to that of functionally equivalent U.S. institutions.
Upstream Bio, Inc. is a clinical-stage biotech focused on verekitug, a monoclonal antibody targeting the TSLP receptor for severe asthma, CRSwNP, and COPD. The company reported a net loss of $39.7 million for the quarter and $80.3 million for the six months ended June 30, 2026, compared with $67.2 million a year earlier.
Collaboration revenue from its Maruho agreement was modest at $1.8 million for the first half. Research and development expenses rose to $72.7 million, driven mainly by advancing Phase 2 programs and Phase 3 planning, while general and administrative expenses were $15.1 million. Cash, cash equivalents and short-term investments totaled $261.3 million, and the company states this should fund operations through 2027. Upstream also has a $150 million at-the-market equity program, of which about $2.1 million has been used so far.
Upstream Bio, Inc. reported second quarter 2026 results and provided an update on development of its lead asset, verekitug, for severe inflammatory respiratory diseases. As of June 30, 2026, cash, cash equivalents and short‑term investments totaled $261.3 million, which the company expects will fund planned operations through 2027.
For the quarter ended June 30, 2026, collaboration revenue was $0.8 million. Research and development expenses were $36.1 million and general and administrative expenses were $7.1 million, leading to a net loss of $39.7 million, similar to the $40.0 million net loss a year earlier.
Operationally, Upstream highlighted progress toward planned Phase 3 trials of verekitug in severe asthma and CRSwNP targeted for the first quarter of 2027, completion of enrollment in the Phase 2 VENTURE COPD trial with 481 participants, and additional supportive Phase 2 data presentations in CRSwNP and severe asthma.